Literature DB >> 28551376

Regulation of Na+-K+-ATPase effected high glucose-induced myocardial cell injury through c-Src dependent NADPH oxidase/ROS pathway.

Xiaofei Yan1, Meng Xun2, Xiaojuan Dou1, Litao Wu1, Yan Han1, Jin Zheng3.   

Abstract

Depressed Na+/K+-ATPase activity has long been reported to be involved in diabetic-related cardiomyocyte death and cardiac dysfunction. However, the nature of directly regulating Na+-K+-ATPase in diabetic-related myocardial diseases remains unknown. Hyperglycemia is believed as one of major factors responsible for diabetic-related myocardial apoptosis and dysfunction. In this study, whether inhibiting Na+-K+-ATPase by ouabain or activating Na+-K+-ATPase by DRm217 has functions on high glucose (HG) -induced myocardial injury was investigated. Here we found that addition of DRm217 or ouabain to HG-treated cells had opposite effects. DRm217 decreased but ouabain increased HG-induced cell injury and apoptosis. This was mediated by changing Na+-K+-ATPase activity and Na+-K+-ATPase cell surface expression. The inhibition of Na+-K+-ATPase endocytosis alleviated HG-induced ROS accumulation. Na+-K+-ATPase·c-Src dependent NADPH oxidase/ROS pathway was also involved in the effects of ouabain and DRm217 on HG-induced cell injury. These novel results may help us to understand the important role of the Na+-K+-ATPase in diabetic cardiovascular diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DRm217; High glucose; NADPH oxidase; Na(+)-K(+)-ATPase; Ouabain; ROS; c-Src

Mesh:

Substances:

Year:  2017        PMID: 28551376     DOI: 10.1016/j.yexcr.2017.05.023

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Predictive Value of Fasting Blood Glucose for Microvascular Obstruction in Nondiabetic Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention.

Authors:  Han Wu; Ran Li; Kun Wang; Dan Mu; Jian-Zhou Chen; Xuan Wei; Xue Bao; Zhong-Hai Wei; Jun Xie; Biao Xu
Journal:  Cardiol Res Pract       Date:  2020-09-26       Impact factor: 1.866

2.  Cardiac glycoside bufalin blocks cancer cell growth by inhibition of Aurora A and Aurora B activation via PI3K-Akt pathway.

Authors:  Chuan-Ming Xie; Xiao-Tong Lin; Di Wu; Ye Tan; Christopher H K Cheng; Jun Zhang
Journal:  Oncotarget       Date:  2018-02-09

3.  Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats.

Authors:  Alaaeldin Ahmed Hamza; Ebtehal Mohammad Fikry; Wedad Abdallah; Amr Amin
Journal:  Sci Rep       Date:  2018-06-29       Impact factor: 4.379

4.  Effect of photobiomodulation therapy on neuronal injuries by ouabain: the regulation of Na, K-ATPase; Src; and mitogen-activated protein kinase signaling pathway.

Authors:  Yun-Hee Rhee; Jeong Hwan Moon; Jae Yun Jung; Connie Oh; Jin-Chul Ahn; Phil-Sang Chung
Journal:  BMC Neurosci       Date:  2019-04-26       Impact factor: 3.288

5.  Halofuginone protects against advanced glycation end products‑induced injury of H9C2 cells via alleviating endoplasmic reticulum stress‑associated apoptosis and inducing autophagy.

Authors:  Yu-Hui Li; Wei-Li Zhang; Hao-Ying Zhou; Da-Wei Yu; Xiao-Ning Sun; Qin Hu
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

6.  Stimulation of Na+/K+-ATPase with an Antibody against Its 4th Extracellular Region Attenuates Angiotensin II-Induced H9c2 Cardiomyocyte Hypertrophy via an AMPK/SIRT3/PPARγ Signaling Pathway.

Authors:  Siping Xiong; Hai-Jian Sun; Lei Cao; Mengyuan Zhu; Tengteng Liu; Zhiyuan Wu; Jin-Song Bian
Journal:  Oxid Med Cell Longev       Date:  2019-09-15       Impact factor: 6.543

7.  DR-region of Na+/K+-ATPase is a target to ameliorate hepatic insulin resistance in obese diabetic mice.

Authors:  Hai-Jian Sun; Lei Cao; Meng-Yuan Zhu; Zhi-Yuan Wu; Chen-You Shen; Xiao-Wei Nie; Jin-Song Bian
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.